SEC Form SC 13G/A filed by Pacific Biosciences of California Inc. (Amendment)

$PACB
Biotechnology: Laboratory Analytical Instruments
Industrials
Get the next $PACB alert in real time by email
SC 13G/A 1 pacbio130247sc13ga2.htm AMENDMENT NO. 2

 

 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION 

Washington, D.C. 20549

 ________________ 

  

SCHEDULE 13G/A

 

Under the Securities Exchange Act of 1934

 

(Amendment No. 2)*

 

 

Pacific Biosciences of California, Inc.
(Name of Issuer)
 
Common Stock, par value $0.001 per share
(Title of Class of Securities)
 
69404D108
(CUSIP Number)
 
December 31, 2023
(Date of Event which Requires Filing of this Statement)

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

 

x       Rule 13d-1(b)

 

o       Rule 13d-1(c)

 

o       Rule 13d-1(d)

 

 

                                                             

* The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

 

The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

 

 

 

 Page 1 of 9 
 

 

CUSIP No. 69404D108                 13G/A  

 

1.

NAMES OF REPORTING PERSONS

 

Sumitomo Mitsui Trust Holdings, Inc.  (“SMTH”)

  

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) o
   

(b) o

 

3.

SEC USE ONLY

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Japan

 

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5.

SOLE VOTING POWER

0

 

6.

SHARED VOTING POWER

13,200,375

 

7.

SOLE DISPOSITIVE POWER

0

 

8.

SHARED DISPOSITIVE POWER

13,200,375

 

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

13,200,375

 

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

 

o

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

4.93%

12.

TYPE OF REPORTING PERSON (see instructions)

 

HC, FI

 

 Page 2 of 9 
 

  

CUSIP No. 69404D108 13G/A  

 

1.

NAMES OF REPORTING PERSONS

 

Nikko Asset Management Co., Ltd. (“NAM”)

    

2. CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (a) o
   

(b) o

 

3.

SEC USE ONLY

 

4.

CITIZENSHIP OR PLACE OF ORGANIZATION

 

Japan

 

NUMBER OF
SHARES
BENEFICIALLY
OWNED BY
EACH
REPORTING
PERSON WITH
5.

SOLE VOTING POWER

0

 

6.

SHARED VOTING POWER

13,200,375

 

7.

SOLE DISPOSITIVE POWER

0

 

8.

SHARED DISPOSITIVE POWER

13,200,375

 

9.

AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

 

13,200,375

 

10.

CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see instructions)

 

o

11.

PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

 

4.93%

12.

TYPE OF REPORTING PERSON

 

IA, HC, FI

 

 

 Page 3 of 9 
 

  

Item 1(a).Name of Issuer:

 

Pacific Biosciences of California, Inc.

 

Item 1(b).Address of Issuer’s Principal Executive Offices:

 

1305 O’Brien Drive Menlo Park, California 94025

 

Item 2(a).Name of Person Filing:

 

Sumitomo Mitsui Trust Holdings, Inc.

 

Nikko Asset Management Co., Ltd.

 

Item 2(b).Address of Principal Business Office or, if None, Residence:

 

SMTH: 1-4-1 Marunouchi, Chiyoda-ku, Tokyo 100-8233, Japan

 

NAM: Midtown Tower, 9-7-1 Akasaka, Minato-ku, Tokyo 107-6242, Japan

 

Item 2(c).Citizenship:

 

SMTH: Japan

 

NAM: Japan

 

Item 2(d).Title of Class of Securities:

 

Common Stock, par value $0.001 per share

 

Item 2(e).CUSIP Number:

 

69404D108

 

 Page 4 of 9 
 

 

Item 3.If this Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

 

SMTH:

 

 

(a) o  Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
     
(b) o  Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
     
(c) o  Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
     
(d) o  Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
(e) o  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
(f) o  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
(g) x  A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
(h) o  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
(i) o  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
(j) x  A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
(k) o  Group, in accordance with §240.13d-1(b)(1)(ii)(K).

 

If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: Parent Holding Company

 

NAM:

 

(a) o  Broker or dealer registered under Section 15 of the Act (15 U.S.C. 78o);
     
(b) o  Bank as defined in Section 3(a)(6) of the Act (15 U.S.C. 78c);
     
(c) o  Insurance company as defined in Section 3(a)(19) of the Act (15 U.S.C. 78c);
     
(d) o  Investment company registered under Section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
     
(e) x  An investment adviser in accordance with §240.13d-1(b)(1)(ii)(E);
     
(f) o  An employee benefit plan or endowment fund in accordance with §240.13d-1(b)(1)(ii)(F);
     
(g) x  A parent holding company or control person in accordance with §240.13d-1(b)(1)(ii)(G);
     
(h) o  A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
     
(i) o  A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
     
(j) x  A non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J);
     
(k) o  Group, in accordance with §240.13d-1(b)(1)(ii)(K).

 

 Page 5 of 9 
 

  

If filing as a non-U.S. institution in accordance with §240.13d-1(b)(1)(ii)(J), please specify the type of institution: Investment Adviser, Parent Holding Company

 

Item 4.Ownership.

 

Provide the following information regarding the aggregate number and percentage of the class of securities of issuer identified in Item 1.

 

SMTH:    
     
  (a)   Amount beneficially owned: 13,200,375
       
  (b)   Percent of class: 4.93%
       
  (c)   Number of shares as to which such person has:
       
  (i)   Sole power to vote or to direct the vote: 0
       
  (ii)   Shared power to vote or to direct the vote: 13,200,375
       
  (iii)   Sole power to dispose or to direct the disposition of: 0
       
  (iv)  

Shared power to dispose or to direct the disposition of: 13,200,375

       
NAM:    
     
  (a)   Amount beneficially owned: 13,200,375
       
  (b)   Percent of class: 4.93%
       
  (c)   Number of shares as to which such person has:
       
  (i)   Sole power to vote or to direct the vote: 0
       
  (ii)   Shared power to vote or to direct the vote: 13,200,375
       
  (iii)   Sole power to dispose or to direct the disposition of: 0
       
  (iv)   Shared power to dispose or to direct the disposition of: 13,200,375

 

 Page 6 of 9 
 

 

Item 5.Ownership of Five Percent or Less of a Class.

  

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following. x

 

Item 6.Ownership of More than Five Percent on Behalf of Another Person.

 

Not applicable.

 

Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company.

 

See Exhibit A.

 

Item 8.Identification and Classification of Members of the Group.

 

Not applicable.

 

Item 9.Notice of Dissolution of Group.

 

Not applicable.

 

Item 10.Certifications.

 

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

 

 Page 7 of 9 
 

  

SIGNATURE

 

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

 

Date: February 5, 2024

 

  Sumitomo Mitsui Trust Holdings, Inc.
  (Company)
   
  /s/ Hideaki Takamiya
 

(Signature)

 

Hideaki Takamiya / Senior Manager of Risk
Management Dept 

  (Name/Title)
   
  Nikko Asset Management Co.,Ltd 
  (Company)
   
  /s/ Atsushi Ohya
 

(Signature)

 

Atsushi Ohya / Head of Business Regulatory Compliance 

  (Name/Title)

 

 Page 8 of 9 
 

  

Exhibit A

 

Pursuant to the instructions in Item 7 of Schedule 13G, the securities being reported on by each of SMTH and NAM, as parent holding companies, are owned, or may be deemed to be beneficially owned, by their subsidiary Nikko Asset Management Americas, Inc., which is classified as an investment adviser in accordance with §240.13d-1(b)(1)(ii)(E).

 

 

Page 9 of 9

 

 

Get the next $PACB alert in real time by email

Chat with this insight

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$PACB

DatePrice TargetRatingAnalyst
11/11/2024Buy → Neutral
UBS
6/3/2024$4.00Buy
Jefferies
4/22/2024Overweight → Neutral
JP Morgan
4/18/2024$7.00 → $2.50Buy → Neutral
Goldman
12/14/2023$11.00Overweight
Stephens
12/14/2023Neutral
Guggenheim
12/13/2023Peer Perform
Wolfe Research
11/17/2023$13.00 → $10.00Neutral → Buy
UBS
More analyst ratings

$PACB
Press Releases

Fastest customizable press release news feed in the world

See more
  • Scientists Solve One of Genomics' Biggest Challenges by Using HiFi Sequencing to Distinguish Highly Similar Paralogous Genes

    MENLO PARK, Calif., March 17, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced a newly published study in Nature Communications unveiling a powerful new method for analyzing some of the most complex regions of the human genome. Led by researchers from PacBio, GeneDx, and a global consortium of genomics experts, the study utilizes Paraphase, an informatics tool that, when paired with HiFi long-read sequencing, allows for high-precision variant detection and copy number analysis in 316 previously inaccessible segmental duplication regions, including 9 challenging medically-relevant genes. Segmental dupli

    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • PacBio to Participate in TD Cowen's 45th Annual Health Care Conference

    MENLO PARK, Calif., Feb. 19, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that management will be presenting at TD Cowen's 45th Annual Health Care Conference on Tuesday, March 4, 2025, at 3:10 PM ET (12:10 PM PT) in Boston, MA. A live webcast of the event can be accessed at the company's investors page at investor.pacificbiosciences.com. A replay of the webcast will be available for at least 30 days following the event. About PacBio PacBio (NASDAQ:PACB) is a premier life science technology company that designs, develops, and manufactures advanced sequencing solutions to help scientists and clini

    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • PacBio Grants Equity Incentive Award to New Employee

    MENLO PARK, Calif., Feb. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading provider of high-quality, highly accurate sequencing platforms, today announced that the Compensation Committee of the Company's Board of Directors granted a non-qualified stock option (the "Option") covering 400,000 shares of PacBio common stock, and restricted stock units ("RSUs") covering 300,000 shares of PacBio common stock to a recently hired employee under the Pacific Biosciences 2020 Inducement Equity Incentive Plan (the "2020 Inducement Plan"), effective on February 10, 2025. The award was granted as an inducement material to such individual's entering into employment with PacBio in accordance wi

    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$PACB
Analyst Ratings

Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

See more

$PACB
Insider Purchases

Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

See more

$PACB
Insider Trading

Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

See more

$PACB
SEC Filings

See more

$PACB
Leadership Updates

Live Leadership Updates

See more
  • PacBio Announces Appointment of David Ruggiero as Head of Global Sales & Service

    MENLO PARK, Calif., Feb. 03, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of David Ruggiero as the company's new Global Head of Sales & Service. Mr. Ruggiero brings over two decades of experience in sales leadership within the technology and life sciences sectors. Prior to joining PacBio, he served as Senior Vice President, North America for Sinch AB, a leading global provider of cloud-based communication solutions for business and mobile operators. In his role he led North American sales for the enterprise, mid-market segments. Before that, he held senior sales positions at Zoom V

    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • PacBio Announces Appointment of Chris Smith to Board of Directors

    MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced the appointment of Chris Smith to its Board of Directors, effective today. Mr. Smith is currently the Chief Executive Officer of NeoGenomics, Inc. (NASDAQ:NEO), a leading oncology testing services company. Mr. Smith, a seasoned executive with extensive experience in the life sciences and healthcare industries, brings a strong track record of leadership in genomics, diagnostics, and corporate strategy. As CEO of NeoGenomics, a leading provider of oncology testing services, he has overseen the company's continued growth and in

    $NEO
    $PACB
    Precision Instruments
    Health Care
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • PacBio Announces the Retirement of David Botstein, Ph.D., from its Board of Directors

    MENLO PARK, Calif., Dec. 11, 2023 /PRNewswire/ -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced today that David Botstein, Ph.D., a member of PacBio's Board of Directors, has retired from his position effective December 7, 2023.   "I would like to thank David for his dedication to PacBio since he joined the Board in 2012," said Christian Henry, President and Chief Executive Officer. "His deep understanding of genomics and broad experience in technological innovation in the field has made him a valuable leader as PacB

    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$PACB
Financials

Live finance-specific insights

See more
  • PacBio Announces Fourth Quarter and Fiscal Year 2024 Financial Results

    MENLO PARK, Calif., Feb. 13, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) today announced financial results for the quarter and fiscal year ended December 31, 2024. Fourth quarter results Revenue of $39.2 million, a 33% decrease compared with $58.4 million in the prior-year period.Instrument revenue of $15.3 million compared with $35.1 million in the prior-year period. Instrument revenue in the fourth quarter of 2024 included 23 Revio® sequencing systems and 7 Vega™ sequencing systems.Consumables revenue of $18.8 million compared with $18.9 million in the prior-year period.Service and other revenue of $5.1 million compared with $4.4 million in the prior-year period. Gross margin, opera

    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • PacBio to Report Fourth Quarter 2024 Financial Results on February 13, 2025

    MENLO PARK, Calif., Jan. 30, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB) announced today that it will hold its quarterly conference call to discuss its fourth quarter 2024 financial results on Thursday, February 13, 2025, at 4:30 pm Eastern Time. The call will be webcast and may be accessed at PacBio's website at https://investor.pacificbiosciences.com/. Date: Thursday, February 13, 2025, at 4:30 pm ET (1:30 pm PT)Listen live via internet or replay: https://investor.pacificbiosciences.com/Toll-free: 1-888-349-0136International: 1-412-317-0459 If using the dial-in option, please join the call ten minutes before the start time using the appropriate number above and ask to join the

    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials
  • PacBio Announces Preliminary Fourth Quarter and Full Year Revenue

    Commenced shipment of the Vega™ benchtop system ahead of schedule, bringing HiFi sequencing to more customers Launched SPRQ chemistry, enabling the sub-$500 HiFi genome on the Revio® system MENLO PARK, Calif., Jan. 14, 2025 (GLOBE NEWSWIRE) -- PacBio (NASDAQ:PACB), a leading developer of high-quality, highly accurate sequencing solutions, announced preliminary unaudited revenue for the fourth quarter of 2024 and full year 2024 of $39.2 million and $154.0 million representing a year-over-year decline of 33% and 23%, respectively. "Though challenging, 2024 was a productive year for PacBio as we launched groundbreaking products, strengthened our balance sheet, and made significant pr

    $PACB
    Biotechnology: Laboratory Analytical Instruments
    Industrials

$PACB
Large Ownership Changes

This live feed shows all institutional transactions in real time.

See more